

D¹
cont

or 29 having a deletion, substitution, addition or modification of at least one amino acid, wherein the heparin-binding protein comprising at least one sugar chain has FGF activity and wherein the peptide to which the sugar chain can be added comprises a proteoglycan core protein or a part thereof.

D²
sub-F4

16. (Amended) A heparin binding protein comprising at least one covalently bonded sugar chain, wherein the at least one sugar chain is selected from the group consisting of a sulfated polysaccharide, a glycosaminoglycan, an O-linked sugar chain and combinations thereof, wherein the at least one sugar chain is covalently bonded through a peptide to which the sugar chain can be added.

D³
sub-F5

19. (Amended) A heparin binding protein comprising a plurality of covalently bonded sugar chains, wherein the sugar chains are selected from the group consisting of a sulfated polysaccharide, a glycosaminoglycan, an O-linked sugar chain and combinations thereof, wherein the sugar chain is covalently bonded through a peptide to which the sugar chain can be added.

REMARKS

This submission is in response to the Office Action dated October 3, 2000 and supplemental to the response filed on March 5, 2001. Consideration of this application, as amended, is respectfully requested.

Claims 1, 3-6, 14 and 16-22 are pending in this application. In this supplemental response, claims 5, 16 and 19 have been amended in order to more particularly point out and distinctly claim the subject matter that Applicants regard as their invention. No new matter has been added by way of these amendments.


Attached hereto is a marked up version of the changes made to the claims by the current amendment. The attached page is entitled "Version of claim amendments with markings to show changes made."

An early and favorable action on the merits is earnestly solicited.

CONCLUSION

In view of the action taken and arguments made, Applicants believe that claims 1, 3-6, 14 and 16-22 are patentable. An early and favorable action on the merits is earnestly solicited.

Respectfully submitted,
DAVIDSON, DAVIDSON & KAPPEL, LLC



Morey B. Wildes
Reg. No. 36,968

Davidson, Davidson & Kappel, LLC
485 Seventh Avenue, 14th Floor
New York, New York 10018
(212) 736-1940

**VERSION OF CLAIM AMENDMENTS
WITH MARKINGS TO SHOW CHANGES MADE**

5. (Twice Amended) The heparin binding protein of claim 4, wherein the heparin-binding protein comprising the at least one covalently bonded sugar chain comprises:

(a) a protein consisting of the amino acid sequence of SEQ ID NO: 1, 17, 19, 21, 23, or 29; or

(b) a protein which consists of the amino acid sequence of SEQ ID NO: 1, 17, 19, 21, 23, or 29 having a deletion, substitution, addition or modification of at least one amino acid, wherein the heparin-binding protein comprising at least one sugar chain has FGF activity and [the sugar chain can be added thereto] wherein the peptide to which the sugar chain can be added comprises a proteoglycan core protein or a part thereof.

16. (Amended) A heparin binding protein comprising at least one covalently bonded sugar chain, wherein the at least one sugar chain is selected from the group consisting of a sulfated polysaccharide, a glycosaminoglycan, [an N-linked sugar chain,] an O-linked sugar chain and combinations thereof, wherein the at least one sugar chain is covalently bonded through a peptide to which the sugar chain can be added.

19. (Amended) A heparin binding protein comprising a plurality of covalently bonded sugar chains, wherein the sugar chains are selected from the group consisting of a sulfated polysaccharide, a glycosaminoglycan, [an N-linked sugar chain,] an O-linked sugar chain and combinations thereof, wherein the sugar chain is covalently bonded through a peptide to which the sugar chain can be added.